PLoS ONE · 2012 · 112 citations · 17 references
Life SciencesCell BiologyMolecular BiologyCell AdhesionGlycobiologyMolecular OncologyCancer GlycobiologyCell-surface GlycansEpithelial-mesenchymal TransitionEpithelial-to-mesenchymal TransitionGlycan StructureGlycosylation PathwaysAberrant Glycosylation In CancerE-cadherin FunctionE-cadherin LossE-cadherin-mediated AdhesionEnzymatic ChangesGlycosylation MechanismsN-glycosylation In CancerProtein Expression Levels
BACKGROUND: N-acetylglucosaminyltransferase-III (GnT-III) is a glycosyltransferase encoded by Mgat3 that catalyzes the addition of β1,4-bisecting-N-acetylglucosamine on N-glycans. GnT-III has been pointed as a metastases suppressor having varying effects on cell adhesion and migration. We have previously described the existence of a functional feedback loop between E-cadherin expression and GnT-III-mediated glycosylation. The effects of GnT-III-mediated glycosylation on E-cadherin expression and cellular phenotype lead us to evaluate Mgat3 and GnT-III-glycosylation role during Epithelial-Mesenchymal-Transition (EMT) and the reverted process, Mesenchymal-Epithelial-Transition (MET). METHODOLOGY/PRINCIPAL FINDINGS: We analyzed the expression profile and genetic mechanism controlling Mgat3 expression as well as GnT-III-mediated glycosylation, in general and specifically on E-cadherin, during EMT/MET. We found that during EMT, Mgat3 expression was dramatically decreased and later recovered when cells returned to an epithelial-like phenotype. We further identified that Mgat3 promoter methylation/demethylation is involved in this expression regulation. The impact of Mgat3 expression variation, along EMT/MET, leads to a variation in the expression levels of the enzymatic product of GnT-III (bisecting GlcNAc structures), and more importantly, to the specific modification of E-cadherin glycosylation with bisecting GlcNAc structures. CONCLUSIONS/SIGNIFICANCE: Altogether, this work identifies for the first time Mgat3 glycogene expression and GnT-III-mediated glycosylation, specifically on E-cadherin, as a novel and major component of the EMT/MET mechanism signature, supporting its role during EMT/MET.
17
Paul Flicek, M Ridwan Amode, Daniel Barrell et al. · Nucleic Acids Research · 2010 · 599 citations · Full text
Karsten Gravdal, Ole J. Halvorsen, Svein A. Haukaas et al. · Clinical Cancer Research · 2007 · 563 citations
The CpG island searcher: a new WWW resource.
Daiya Takai, Peter A. Jones · PubMed · 2003 · 350 citations